The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Fixed-duration epcoritamab + R-CHOP in newly diagnosed higher-risk DLBCL: follow-up of EPCORE NHL-2
Lorenzo Falchi, MD, Memorial Sloan Kettering Cancer Center, New York, NY, outlines the findings from the 38.8-month follow-up of the EPCORE NHL-2 trial (NCT04663347), specifically of the arm comparing fixed-duration epcoritamab plus R-CHOP to R-CHOP alone in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) and high International Prognostic Index (IPI) scores. Dr Falchi highlights that the results have been encouraging, with many patients achieving deep and durable responses. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
EPCORE-NHL2 was a multi-arm phase 1-2 study conducted internationally, and it really was aimed at testing the bispecific antibody epcoritamab in combination with a variety of standards of care for patients with B-cell lymphoma, including large B-cell lymphoma and follicular lymphoma. And here at ASH, we presented updated follow-up of our arm 1 study, which tested epcoritamab in combination with R-CHOP for patients with higher risk, newly diagnosed, diffuse large B-cell lymphoma...
EPCORE-NHL2 was a multi-arm phase 1-2 study conducted internationally, and it really was aimed at testing the bispecific antibody epcoritamab in combination with a variety of standards of care for patients with B-cell lymphoma, including large B-cell lymphoma and follicular lymphoma. And here at ASH, we presented updated follow-up of our arm 1 study, which tested epcoritamab in combination with R-CHOP for patients with higher risk, newly diagnosed, diffuse large B-cell lymphoma. And higher risk was defined as an international prognostic index of three to five. The study enrolled 47 patients, and now we’re at 38.8 months follow-up. So a very extended follow-up.
We had already presented the original results with response rates that were very promising and very consistent across risk groups. Here we look at an end-of-treatment response rate of 98%, 85% complete metabolic response rate. And now with an extended follow-up, as I said, of 38.8 months, we really start to see the long-term benefit of adding epcoritamab to standard R-CHOP. Our three-year rate of progression-free survival is at 80%, and 87% of the patients were alive at the same time point. Importantly, the majority of patients with available samples to be tested for minimal residual disease showed a clearance of minimal residual disease by cycle three, day one. That means after just two cycles of therapy. So it’s really deep responses, MRD negative responses, and now we know lasting a long time. These results compare favorably with what we would expect with simple R-CHOP in patients with comparably higher risk disease at the time of diagnosis. So very much hopeful that these results are going to support a positive phase three trial that’s currently ongoing. It will read out in 2026. I’m really hopeful that Epcoritamab will be an added value to R-CHOP, particularly in patients with high-risk DLBCL.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
